Did you know?

Jan 6, 2022 · An Approach to Solving the Complex Clinicogenomic Data Landscape in Precision Oncology: Learnings From the Design of WAYFIND-R, a Global Precision Oncology Registry. Le Tourneau et al. Published online: August 8, 2022. Nov 12, 2022 · PURPOSE Whether germline multigene panel testing (MGPT) should be performed in all individuals with colorectal cancer (CRC) remains uncertain. Therefore, we aimed to determine the yield and potential clinical impact of MGPT across a large, diverse CRC cohort. METHODS This was a retrospective cohort study of adults with CRC who underwent MGPT of > 10 genes at a commercial laboratory between ... DOI: 10.1200/PO.17.00073 JCO Precision Oncology - published online October 3, 2017DOI: 10.1200/PO.17.00073 JCO Precision Oncology - published online October 3, 2017WebJCO Precision Oncology (JCO PO) is a peer-reviewed, online-only, article-based journal publishing original research, reports, opinions, and reviews that advance the science and practice of precision oncology and define genomics-driven clinical care of patients with cancer. DOI: 10.1200/PO.22.00517 JCO Precision Oncology no. 6 (2022) e2200517. Published online November 12, 2022. PMID: 36370464. Multigene Panel Testing Yields High Rates of Clinically Actionable Variants Among Patients With Colorectal Cancer Sarah E. Coughlin, MD 1. x. Sarah E. Coughlin. Search for articles by this author ...May 11, 2022 · DOI: 10.1200/PO.21.00535 JCO Precision Oncology no. 6 (2022) e2100535. Published online May 11, 2022. PMID: 35544728 The Precision Oncology Decision Support system (PODS) was established at The University of Texas MD Anderson Cancer Center in recognition of these needs. 9 Herein, we report our experience with large-scale, institution-wide decision support and its initial clinical utility. These data are among the first to suggest that providing alteration ...JCO Precision Oncology ( JCO PO) is a peer-reviewed, online-only journal publishing original research, reports, opinions, and reviews that advance the science and practice of precision oncology and define genomics- and other biomarker-driven clinical care of patients with cancer. Aug 19, 2021 · DOI: 10.1200/PO.20.00472 JCO Precision Oncology no. 5 (2021) 1312-1324. Published online August 19, 2021. Published online August 19, 2021. Real-World Performance of a Comprehensive Genomic Profiling Test Optimized for Small Tumor Samples CHASTEPA metro station (2nd station), SCHOOL #303. A reliable partner for everyone who cares about their health. We offer a wide range of services, ranging from laboratory and …DOI: 10.1200/PO.22.00531 JCO Precision Oncology no. 7 (2023) e2200531. Published online May 4, 2023. PMID: 37141549. Cyclin-Dependent Kinase 4/6 Inhibitors Beyond Progression in Metastatic Breast Cancer: A Retrospective Real-World Biomarker Analysis Lorenzo Gerratana, MD 1. x. Lorenzo Gerratana. Search for articles by this …The actual frequency of NTRK fusions in thyroid cancer is not known, as some targeted exome sequencing can easily miss fusion event involving introns of certain genes. Studies on frequency of NTRK fusions from a single institution and from the TCGA found NTRK fusion in 10 of 451 (2.2%; four NTRK1 and six NTRK3 fusions) and 12 of 498 (2.4%; five ...Jul 6, 2023 · Pancreatic cancer remains one of the leading causes of cancer-related death, with an estimated 64,050 new cases and 50,550 deaths in the United States in 2023. 1 Among various malignancies, pancreatic cancer is considered highly aggressive and exhibits one of the lowest 5-year survival rates at 10%. 1 Pancreatic ductal adenocarcinoma (PDAC) accounts for approximately 90% of cases of pancreatic ... DOI: 10.1200/PO.19.00339 JCO Precision Oncology no. 4 (2020) 239-243. Published online March 27, 2020. PMID: 35050735. Assessment of Molecular Remission in Oligometastatic Esophageal Cancer With a Personalized Circulating Tumor DNA Assay David J. Einstein, MD 1. x. David J. Einstein. Search for articles by this author ...DOI: 10.1200/PO.18.00114 JCO Precision Oncology - published online February 6, 2019DOI: 10.1200/PO.22.00531 JCO Precision Oncology no. 7 (2023) e2200531. Published online May 4, 2023. PMID: 37141549. Cyclin-Dependent Kinase 4/6 Inhibitors Beyond Progression in Metastatic Breast Cancer: A Retrospective Real-World Biomarker Analysis Lorenzo Gerratana, MD 1. x. Lorenzo Gerratana. Search for articles by this …Most patients are diagnosed with early-stage breast cancer (EBC), which is potentially curable with standard treatments. 3 Although (neo)adjuvant chemotherapies (NAC) reduce the risk of recurrence and death, approximately 30% of patients with EBC will experience recurrence in the first 10 years after surgery. 4 Recent studies have reported that circulating tumor DNA (ctDNA) detection in ...Stage 4 is the final stage of most cancers that have spread to other areas of the body, states the American Society of Clinical Oncology. Cancer stages are usually determined by the size, growth and spread of the cancer.The liquid biopsy NGS assay demonstrated excellent concordance with tissue profiling in this multicenter, prospective, clinical validation study, with sensitivity and specificity equivalent to Food and Drug Administration-approved single-gene ctDNA assays. The use of plasma-based molecular profiling …DOI: 10.1200/PO.20.00037 JCO Precision Oncology no. 4 (2020) 757-766. Published online June 25, 2020. PMID: 35050752. Palbociclib in Patients With Non–Small-Cell Lung Cancer With CDKN2A Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study Eugene R. Ahn, MD 1. x. Eugene R. Ahn ...WebJul 9, 2021 · PURPOSE We conducted this systemThis author is a member of the JCO Preci DOI: 10.1200/PO.21.00181 JCO Precision Oncology no. 6 (2022) e2100181. Published online March 9, 2022. PMID: 35263168. Impact of Circulating Tumor DNA–Based Detection of Molecular Residual Disease on the Conduct and Design of Clinical Trials for Solid Tumors Pashtoon M. Kasi, MD, MS 1. x. Pashtoon M. Kasi. Search for articles by …WebDOI: 10.1200/PO.22.00694 JCO Precision Oncology no. 7 (2023) e2200694. Published online September 1, 2023. PMID: 37656949. Dynamic Monitoring of Circulating Tumor DNA in Patients With Metastatic Colorectal Cancer Milena Urbini, PhD 1. x. Milena Urbini. Search for articles by this author ... DOI: 10.1200/PO.20.00321 JCO Precision Oncology no. 5 (2021 SAMARKAND CHEMICAL. JSC is located at the address: Uzbekistan, 140162, Samarkand region, Samarkand, Kimyogarlar block of flats, Phone number … DOI: 10.1200/PO.21.00011 JCO Precision Oncology no.

This author is a member of the JCO Precision Oncology Editorial Board. Journal policy recused the author from having any role in the peer review of this manuscript. Stock and Other Ownership Interests: TP Therapeutics, Nuvalent, Inc. Honoraria: Natera.JCO Precision Oncology, published online May 14, 2018. https://ascopubs.org/doi/full/10.1200/PO.17.00247. Thyroid Cancer. Busaidy NL, Konda B, Wei L, Wirth LJ ...DOI: 10.1200/PO.21.00011 JCO Precision Oncology no. 5 (2021) 1687-1698. Published online November 3, 2021. Published online November 3, 2021. Therapeutic Actionability of Circulating Cell-Free DNA Alterations in Carcinoma of Unknown PrimaryDOI: 10.1200/PO.17.00073 JCO Precision Oncology - published online October 3, 2017WebStage 4 is the final stage of most cancers that have spread to other areas of the body, states the American Society of Clinical Oncology. Cancer stages are usually determined by the size, growth and spread of the cancer.

Apr 23, 2020 · PURPOSE HER2 is a critical gene that drives various solid tumors in addition to those of breast cancer. For example, HER2 plays a role in non–small-cell lung cancer (NSCLC). Overexpression, amplification, and point mutations in HER2 have been described in patients with NSCLC; however, the potential roles of these alterations remain unclear. METHODS We summarize the evidence regarding the ... May 18, 2021 · From Race-Based to Precision Oncology: Leveraging Behavioral Economics and the Electronic Health Record to Advance Health Equity in Cancer Care Lau-Min et al. Published online: February 17, 2021 JCO Oncology Practice (JCO OP) publishes impactful information and insights to keep oncology ... JCO Precision Oncology is a peer-reviewed, online-only journal ...…

Reader Q&A - also see RECOMMENDED ARTICLES & FAQs. PURPOSE Acute lymphoblastic leukemia (ALL). Possible cause: DOI: 10.1200/PO.20.00109 JCO Precision Oncology no. 4 (2020) 898-911. Published online J.